한글목차

세계 암 진단 시장 규모는 2024년 776억 달러에서 2029년 1,015억 달러로 확대될 것으로 예상되며, 2024년부터 2029년까지 5.5%의 연평균 성장률을 보일 것으로 예측됩니다.

영상 진단 부문 규모는 2024년 531억 달러에서 2029년 678억 달러로 확대될 것으로 예상되며, 같은 기간 CAGR은 5.0%로 추정됩니다.

차세대 시퀀싱(NGS) 부문은 2024년 28억 달러에서 2029년 47억 달러에 달할 것으로 예상되며, 같은 기간 동안 10.7%의 CAGR을 기록할 것으로 예측됩니다.

세계의 암 진단 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규제 환경, 신흥 기술 및 기술 개발 동향, 시장 규모 추정과 예측, 각종 부문별·지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 요약

• 시장 전망
• 조사 범위
• 시장 요약
• 시장 역학과 성장 촉진요인
• 신기술
• 부문 분석
• 지역 분석
• 전략적 대처
• 결론

제2장 시장 개요

• 개요
• 거시경제 요인 분석
• 미중 무역전쟁의 영향
• Porter's Five Forces 분석

제3장 시장 역학

• 중요 포인트
• 시장 성장 촉진요인
• 암 발증률 상승
• 조기 개입과 예방 진단 스크리닝 수요
• 동반진단의 도입 확대
• 세계적인 고령화
• 시장 기회
• 암 검진 확대
• 첨단 기술에 대한 접근성 강화
• 시장 성장 억제요인
• 복잡한 상환 정책
• 암에 대한 인식의 결여
• 암 진단 검사 비용
• 암 진단 턴어라운드 타임
• 시장 과제
• 숙련 전문가의 부족
• 복잡한 샘플 조제와 취급

제4장 규제 상황

• 시장 규제(주요 국가·지역별)
• 미국
• 유럽
• 일본
• 중국

제5장 신기술과 개발

• 신기술
• 암 진단의 AI
• 다발 암조기 발견(MCED)
• 테라노스틱스
• 디지털 병리와 AI의 통합
• 특허 분석
• 중요 포인트

제6장 암 진단 시장

• 부문 내역
• 세계 시장 인사이트
• 시장 내역 : 제품 유형별
• 진단 영상
• 내시경 디바이스
• 종양 바이오마커 검사
• 생검 기기
• 헤마톡실린과 에오신
• 면역조직화학
• ISH(In Situ Hybridization)
• 중합효소 연쇄 반응
• 차세대 시퀀싱
• 기타
• 시장 내역 : 용도별
• 유방암
• 폐암
• 대장암
• 전립선암
• 위암
• 기타
• 시장 내역 : 최종사용자별
• 병원, 암센터, 클리닉
• 진단 영상·표준 실험실
• 기타
• 지역적 내역
• 시장 내역 : 지역별
• 중요 포인트
• 북미
• 유럽
• 아시아태평양
• 남미
• 중동 및 아프리카

제7장 경쟁 정보

• 기업 점유율 분석
• 전략적 대처

제8장 암 진단 시장의 지속가능성 : ESG 관점

• ESG : 소개
• ESG 퍼포먼스 분석
• 환경 퍼포먼스
• 사회적 퍼포먼스
• 거버넌스 퍼포먼스
• BCC에 의한 결론

제9장 부록

• 조사 방법
• 참고문헌
• 약어
• 기업 개요
• ABBOTT
• AGILENT TECHNOLOGIES INC.
• BD
• BIOMERIEUX
• BIO-RAD LABORATORIES INC.
• DANAHER CORP.
• F. HOFFMANN-LA ROCHE LTD.
• GE HEALTHCARE
• ILLUMINA INC.
• KONINKLIJKE PHILIPS N.V.
• MERCK KGAA
• MYRIAD GENETICS INC.
• QIAGEN
• SIEMENS HEALTHINEERS AG
• THERMO FISHER SCIENTIFIC INC.
• ZYTOVISION GMBH
• 기타 신흥 기업

영문목차

The global market for oncology diagnostics is estimated to increase from $77.6 billion in 2024 to reach $101.5 billion by 2029, at a compound annual growth rate (CAGR) of 5.5% from 2024 through 2029.

The diagnostic imaging market for oncology diagnostics is estimated to increase from $53.1 billion in 2024 to reach $67.8 billion by 2029, at a CAGR of 5.0% from 2024 through 2029.

The next-generation sequencing (NGS) market for oncology diagnostics is estimated to increase from $2.8 billion in 2024 to reach $4.7 billion by 2029, at a CAGR of 10.7% from 2024 through 2029.

Report Scope

This report analyzes the oncology diagnostics market and the competitive landscape. The profiles of several leading companies, including their revenues, product portfolios and recent activities are also examined. The report analyzes market dynamics, including drivers, limitations, challenges and opportunities, and discusses current and potential market size. The report will enable companies in the industry to make informed decisions about the production and licensing of goods and services.

The market is divided into the following segments: diagnostic imaging, tumor biomarker tests, endoscopy, biopsy, hematoxylin and eosin (H&E) staining, immunohistochemistry (IHC), in situ hybridization (ISH), polymerase chain reaction (PCR), next generation sequencing (NGS) and others (cytology, microarrays, exosomes, flow cytometry, sanger sequencing, pyrosequencing etc.). The market is segmented by application into breast cancer, lung cancer, colorectal cancer, prostate cancer, gastric cancer and other cancers (lip, oral/cavity, liver/gallbladder, pancreas, melanoma, kidney, bladder, brain, central nervous system, thyroid, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma and leukemia). By end user, the market is segmented into hospitals/cancer centers/clinics, diagnostic imaging centers/reference laboratories, and other end users (physician offices, research, academic institutes, national cancer registries and contract research organizations).

Regional market analysis is provided for North America, Europe, Asia-Pacific, South America and Middle East and Africa. The report also provides country-level analyses of markets and market segments. North America comprises the U.S., Canada and Mexico, while South America includes Brazil, Argentina and the rest of South America. In Europe, major countries covered are Germany, France, the U.K., Italy and Spain, along with the rest of Europe, which includes Switzerland, Denmark, Norway, Poland, Belgium, Austria, the Netherlands, Sweden, Russia and others. The Asia-Pacific region consists of Japan, China and India, as well as the rest of Asia-Pacific (Australia, New Zealand, Taiwan, Singapore, Malaysia, Thailand, the Philippines, South Korea, Indonesia etc.), and the Middle East and Africa.

The base year for the study is 2023, 2024 is the estimated year, with projections through 2029, including compound annual growth rates (CAGRs) for the forecast period.

Report Includes

• 94 data tables and 59 additional tables
• Analyses of global market trends for oncology diagnostics, with market revenue data from 2021 to 2024, forecasts and projected CAGRs through 2029
• Estimates of the size and growth of the global market, and a corresponding market share analysis by product type, application, end user, and region
• Facts and figures pertaining to the major market dynamics, opportunities and challenges, emerging technologies, regulations, and impacts of macroeconomic variables
• Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
• Coverage of treatments in development for late- and early-stage oncolytic viruses, along with epidemiological information, data corresponding to cancer incidence and mortality trends
• Evaluation of recent patent activity featuring key granted and published patents
• Insights into oncology therapeutics research activity, emerging technologies, clinical trials and pipeline products
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Danaher Corp., Agilent Technologies Inc., Siemens Healthineers AG, and GE HealthCare

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Strategic Initiatives
• Conclusion

Chapter 2 Market Overview

• Overview
• Macroeconomic Factors Analysis
• Impact of the U.S.-China Trade War
• Porter's Five Forces Analysis in the Oncology Market
• Potential of New Entrants (Moderate to Low)
• Bargaining Power of Suppliers (Moderate to High)
• Bargaining Power of Buyers (Moderate to High)
• Threat of Substitute Products or Services (Low)
• Industry Rivalry (High)

Chapter 3 Market Dynamics

• Key Takeaways
• Market Drivers
• Rising Incidence of Cancer Cases
• Demand for Earlier Intervention and Preventive Diagnostic Screening
• Growing Adoption of Companion Diagnostics
• Increasing Aging Population Worldwide
• Market Opportunities
• Expanding Cancer Screening
• Enhancing Access to Advanced Technologies
• Market Restraints
• Complex Reimbursement Policies
• Lack of Cancer Awareness
• Cost of Oncology Diagnostic Tests
• Turnaround Time of Oncology Diagnostics
• Market Challenges
• Lack of Skilled Professionals
• Complex Sample Preparation and Handling

Chapter 4 Regulatory Landscape

• Market Regulations, by Top Country/Region
• The U.S.
• Europe
• Japan
• China

Chapter 5 Emerging Technologies and Developments

• Emerging Technologies
• AI in Oncology Diagnostics
• Multi-Cancer Early Detection (MCED)
• Theranostics
• Digital Pathology and AI Integration
• Patent Analysis
• Key Takeaways

Chapter 6 Oncology Diagnostics Market

• Segment Breakdown
• Global Market Insights
• Market Breakdown by Product Type
• Diagnostics Imaging
• Endoscopy Devices
• Tumor Biomarker Tests
• Biopsy Devices
• Hematoxylin and Eosin
• Immunohistochemistry
• In situ Hybridization
• Polymerase Chain Reaction
• Next-Generation Sequencing
• Others
• Market Breakdown by Application
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Gastric Cancer
• Other Applications
• Market Breakdown by End User
• Hospitals, Cancer Centers and Clinics
• Diagnostic Imaging and Reference Laboratories
• Others
• Geographic Breakdown
• Market Breakdown, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa (MEA)

Chapter 7 Competitive Intelligence

• Company Share Analysis
• Strategic Initiatives

Chapter 8 Sustainability in the Market for Oncology Diagnostics: An ESG Perspective

• Introduction to ESG
• ESG Performance Analysis
• Environmental Performance
• Social Performance
• Governance Performance
• Concluding Remarks from BCC

Chapter 9 Appendix

• Research Methodology
• References
• Abbreviations
• Company Profiles
• ABBOTT
• AGILENT TECHNOLOGIES INC.
• BD
• BIOMERIEUX
• BIO-RAD LABORATORIES INC.
• DANAHER CORP.
• F. HOFFMANN-LA ROCHE LTD.
• GE HEALTHCARE
• ILLUMINA INC.
• KONINKLIJKE PHILIPS N.V.
• MERCK KGAA
• MYRIAD GENETICS INC.
• QIAGEN
• SIEMENS HEALTHINEERS AG
• THERMO FISHER SCIENTIFIC INC.
• ZYTOVISION GMBH
• Other Emerging Players in the Oncology Diagnostics Market